Showing posts with label UCB Derived hMSCs. Show all posts
Showing posts with label UCB Derived hMSCs. Show all posts

Sunday, March 26, 2017

Targeted Delivery of Our UCB Derived hMSCs

Liver-targeting Delivery via Intravenous Injection of Cells

Check out how our UCB Human Mesenchymal Stem Cells are engineered for delivery to the liver: Hahn, Sei Kwang (Pohang-si, KR), Kim, Yun Seop (Seoul, KR), Kong, Won Ho (Pohang-si, KR),Kim, Hyemin (Daegu, KR). HYALURONIC ACID DERIVATIVES AND COMPOSITION FOR CELL-SURFACE ENGINEERING USING THE SAME. United States Patent Application 20170067012.
Images: Neuromics' hMSCS in culture
Preparation method of a hyaluronic acid derivative capable of modifying the surface of cells and also having biocompatibility, biodegradability, and liver-targeting deliver property, and use of the hyaluronic acid derivative prepared thereby as a liver-targeting cell delivery system.

Tuesday, August 23, 2016

Human Mesenchymal Stem Cells Conjugates

Targeted Delivery of Stem Cells
Here's a recent publication referencing use of our Human Mesenchymal Stem Cells to form conjugates that could have application for drug delivery and cell therapies: Yun Seop Kim, Won Ho Kong, Hyemin Kim, Sei Kwang Hahn. Targeted Systemic Mesenchymal Stem Cell Delivery Using Hyaluronate - Wheat Germ Agglutinin Conjugate. http://dx.doi.org/10.1016/j.biomaterials.2016.08.027


Images: Fluorescence microscopic images of dissected livers and lungs from normal rats 4 h after intravenous injection of PBS, WGA-FITC/hMSC, and HA-WGA-FITC/hMSC (Filter for FITC). (b) Quantification of hMSCs in dissected organs estimated from ROI (n = 3). **P versus the WGA/hMSC group. (c) Representative fluorescence microscopic images of WGA-FITC/hMSC and HA-WGA-FITC/hMSC in the liver and lung (green = FITC, blue = DAPI for nucleus). Arrows indicate the location of hMSCs (scale bar = 200 μm). http://dx.doi.org/10.1016/j.biomaterials.2016.08.027
Protocol: Cultured MSCs were trypsinized, washed, and resuspended at 1 × 106 cells/mL in PBS. HA-WGA conjugate at 10 μg/mL of WGA was added to MSCs in suspension, and incubated in an ice bath for 10 min with mild mixing. To remove the unbound HA-WGA conjugate to MSCs, cell suspension was washed with PBS and collected by centrifugation (1000 × g, 3 min at 4 °C). After surface modification with HA-WGA conjugate, HA-WGA/hMSC were resuspended in the cell culture medium on 96-well plates (1 × 104 cells per well). At the predetermined time, cell viability of HA-WGA/hMSC was measured using an EZ-cytox cell viability assay kit according to the manufacturer’s instructions. Zeta potentials were analyzed using a Zetasizer Nano (Malvern Instruments, UK) to assess the change of surface charge after the surface modification.
Conclusions: Researchers successfully developed a target-specific systemic delivery system of MSCs to the liver using HA-WGA conjugate. HA-WGA conjugate was synthesized by the coupling reaction of HA-aldehyde with amine group of WGA. GPC analysis revealed the successful synthesis of HA-WGA conjugate. CD analysis corroborated that the secondary structure of WGA remained stable even after conjugation to HA. HA-WGA conjugate appeared to bind to the surface of MSCs and remain stably for up to 1 h. After cell surface modification, most of HA-WGA/MSC complex could be systemically delivered to the liver 4 h after intravenous injection, whereas MSCs were trapped mainly in the lung. This new strategy to target-specifically deliver MSCs to the liver using HA-WGA conjugate might be successfully exploited for treatment of various liver diseases.

We will continue to post new applications developed by users of our Stem Cells.

Wednesday, August 27, 2014

UCB Derived hMSC-MSCGro™ Media-The Wow Factor!

Neuromics-Vitro Biopharma Cells and Media Used to Treat Cerebral Ischemia

I have frequently posted successful outcomes with our Umbilical Cord Blood Derived Human Mesenchymal Stem Cells and MSCGro Expansion Media. These solutions have been tested head to head with other cell and media options and proven superior in cell behavior, doubling time and total number of passages. Competitive testing, until now, was done in culture.

I am pleased to present a study where our cells and media were selected for the the in vivo treatment of Cerebral Ischemia in Rats. This is a key part of building the foundation for human clinical trials: Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Veeravalli KK. Stem cell treatment after cerebral ischemia regulates the gene expression of apoptotic molecules. Neurochemical research. 39(8): 1511-21 DOI: 10.1007/s11064-014-1341-z
Protocol: Cryo-preserved hUCBSCs obtained from Neuromics/Vitro Biopharma (Golden, CO) were used to establish cultures in MSC-GRO low serum complete MSC medium according to the provided instructions. Cultures were maintained at 37 C in a humidified atmosphere containing 5 % CO2 with a change of culture medium twice a week. When the cell cultures were about 80 % to 90 % confluent, cells were split and subcultured. Cells were detached, washed twice with sterile phosphate buffered saline (PBS), counted and suspended in sterile saline prior to intravenous administration. The cells were intravenously injected (0.25 × 10(6) cells or 1 × 10(6) cells) via the tail vein.
Results:

Fig: Stem cell treatment after MCAO procedure reduces caspase-dependent apoptosis and brain damage. a Green fluorescence indicates cleaved caspase 3 protein expression. Representative cleaved caspase3 images were merged with respective DAPI images. Scale bar 100 lm. b Quantification of cleaved caspase-3 protein expression in the ipsilateral hemisphere of untreated [15] and hUCBSCs-treated animals. n C 3. Values are expressed as mean ± SEM; *p\0.05 compared to untreated MCAO subjected animals. c Representative hematoxylin and eosin stained paraffinembedded tissue sections from rat brains. Higher magnification images from the ischemic cortex and striatal regions of MCAOsubjected and untreated animals show interstitial edema and damaged neurons that have a condensed, irregular shaped and darkly stained nuclei which are absent or less frequent in control/hUCBSCs-treated brain sections. Each group consisted of a minimum of three animals. Scale bar value for the magnified images = 100 lm

This provides an in-depth understanding of the molecular mechanisms underlying the neuroprotective effects of mesenchymal stem cells derived from human umbilical cord blood in a rat model of transient focal cerebral ischemia. The study clearly demonstrates the potential of hUCBSCs to regulate various molecules responsible for cell death after transient focal cerebral ischemia followed by reperfusion.

There are some other important factors to consider:

  • Potency and Number of Stem Cells Matter-To move this into clinical applications, Doctors must be allowed to expand Mesenchymal Stem Cells.
  • Media used Matters-it must be best in class and not initiate immune inflammatory response.

We will continue to post studies utilizing Neuromics' Stem Cell Solutions.